SYNDAX PHARMACEUTICALS INC. overview

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Feb. 4, 2025 WALTHAM, Mass. , Feb. 4, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on February 1, 2025 the Company granted inducement awards to purchase up to 124,000 shares of common stock to six new employees under the Company's 2023 Inducement...

Syndax Announces Participation in February Investor Conferences PR Newswire WALTHAM, Mass., Jan. 30, 2025 WALTHAM, Mass. , Jan. 30, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , Chief Executive Officer of Syndax, as well as members of the Syndax management team, will participate in the following upcoming investor conferences: Guggenheim SMID...

Syndax Highlights Recent Accomplishments and Anticipated 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire WALTHAM, Mass., Jan. 13, 2025 – Launched Revuforj ® (revumenib) for treatment of R/R acute leukemia with a KMT2A translocation in adult and pediatric patients one year and older – – Revumenib added to NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ® ) for AML and ALL – – Niktimvo™ (axatilimab-csfr) approved by U.S. FDA for...

Kuehn Law Encourages Investors of Syndax Pharmaceuticals, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 7, 2025 NEW YORK , Jan. 7, 2025 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing. Shareholders may be entitled to damages and corporate governance reforms. If you are a...

Syndax Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference PR Newswire WALTHAM, Mass., Jan. 7, 2025 WALTHAM, Mass. , Jan. 7, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , Chief Executive Officer of Syndax, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025 at 10:30 a.m. PT / 1:30...

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire WALTHAM, Mass., Jan. 3, 2025 WALTHAM, Mass. , Jan. 3, 2025 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that on January 1, 2025 the Company granted inducement awards to purchase up to 123,100 shares of common stock to five new employees under the Company's 2023 Inducement...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire NEW YORK, Dec. 19, 2024 NEW YORK , Dec. 19, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX). If you are...

Syndax Announces Additional Positive Data for Revuforj® (revumenib) from AUGMENT-101 Trial in Relapsed or Refractory mNPM1 AML and BEAT AML Frontline Combination Trial PR Newswire WALTHAM, Mass., Dec. 9, 2024 – Subgroup analyses from Ph 2 protocol-defined R/R mNPM1 AML efficacy population (N=64) show responses across all major subgroups, including heavily pretreated patients – – 26% CR+CRh (20/77) and 48% ORR (37/77) in all enrolled patients who met the efficacy evaluable criteria in Ph 2...